1 |
Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry").
62
|
Erton ZB...Erkan D
|
36206383 |
2022 |
2 |
Vascular Disease Patient Information Page: Livedoid vasculopathy.
62
|
Eswaran H...Moll S
|
36285833 |
2022 |
3 |
Livedoid vasculopathy: A review with focus on terminology and pathogenesis.
62
|
Eswaran H...Moll S
|
36285834 |
2022 |
4 |
Botulinum toxin-A: A novel treatment for livedoid vasculopathy.
62
|
Crotty AM...Wright KT
|
36186404 |
2022 |
5 |
Livedoid vasculopathy and peripheral neuropathy: A retrospective cohort study of 55 Chinese patients and literature review.
62
|
Gao Y...Jin H
|
36333819 |
2022 |
6 |
Refractory livedoid vasculopathy successfully treated with baricitinib.
62
|
Xiao Y...Li W
|
36349427 |
2022 |
7 |
Clinical, Laboratory, Histopathological and Therapeutic Profile of Livedoid Vasculopathy: A Case Series of 17 Patients.
62
|
Shah SR...Shah BJ
|
36386750 |
2022 |
8 |
Clinical analysis of skin lesions in livedoid vasculopathy: a study of 46 Chinese patients.
62
|
Zhao C...Feng S
|
36411590 |
2022 |
9 |
Livedoid Vasculopathy Associated With Plasminogen Activator Inhibitor-1 Polymorphisms Treated With Factor Xa Inhibitors.
62
|
Bouceiro-Mendes R...Filipe P
|
35636505 |
2022 |
10 |
Efficacy of adalimumab in the treatment of refractory livedoid vasculopathy: Case report and literature review.
62
|
Dong L...Zhang X
|
35760761 |
2022 |
11 |
Excellent Long-term Clinical Response to Rivaroxaban in Livedoid Vasculopathy: A Retrospective Study.
62
|
Morgado-Carrasco D...Mascaro-Galy JM
|
36115384 |
2022 |
12 |
Platelet count and plateletcrit: Potential haematological biomarkers for livedoid vasculopathy?
62
|
Gao Y...Jin H
|
35635484 |
2022 |
13 |
Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.
62
|
Ramphall S...Venugopal S
|
36051980 |
2022 |
14 |
Refractory livedoid vasculopathy in a child successfully treated with baricitinib.
62
|
Zhang H...Liu Y
|
35726859 |
2022 |
15 |
A novel combination ("CHAP") regimen for management of livedoid vasculopathy in 12 patients.
62
|
Coromilas AJ...Micheletti RG
|
35787412 |
2022 |
16 |
Peripheral neuropathy and livedoid vasculopathy.
62
|
Soulages A...Mathis S
|
35166926 |
2022 |
17 |
Patients with laboratory criteria of anti-phospholipid syndrome and 'non-criteria' manifestations: a multicenter cohort.
62
|
Pires da Rosa G...Cervera R
|
35723613 |
2022 |
18 |
Treatment of Livedoid Vasculopathy With Baricitinib.
62
|
Song X...Tu P
|
35353137 |
2022 |
19 |
Adalimumab in Treating Refractory Livedoid Vasculopathy.
62
|
Huang XW...Li L
|
35455298 |
2022 |
20 |
Exacerbation of livedoid vasculopathy after coronavirus disease 2019.
62
|
Kawabe R...Fujimoto M
|
35171794 |
2022 |
21 |
Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.
62
|
Gao Y...Jin H
|
32116074 |
2022 |
22 |
Real-world data on pain management and effectiveness of anti-tumour necrosis factor agents in refractory livedoid vasculopathy.
62
|
Gao Y...Jin H
|
34416092 |
2022 |
23 |
Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.
62
|
Han Y...Tu P
|
36389811 |
2022 |
24 |
Medium-pressure hyperbaric oxygen therapy for livedoid vasculopathy.
62
|
Herrera-Sanchez A...Verdini F
|
35904919 |
2022 |
25 |
Efficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review.
62
|
Gao Y...Jin H
|
35634570 |
2022 |
26 |
Livedoid Vasculitis in a Patient With Sjogren Syndrome Successfully Treated With Methotrexate.
62
|
Aldehaim AY...Alarfaj AS
|
35342318 |
2022 |
27 |
Livedoid vasculopathy - A diagnostic and therapeutic challenge.
62
|
Burg MR...Schneider SW
|
36262273 |
2022 |
28 |
Primary and Secondary Livedoid Vasculopathy: A Report of 2 Cases.
62
|
AboElnasr LS...Aiad HAS
|
34889819 |
2022 |
29 |
Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.
62
|
Bilgic A...Alpsoy E
|
35024414 |
2021 |
30 |
Livedoid vasculopathy and its association with genetic variants: A systematic review.
62
|
Gao Y...Jin H
|
33686673 |
2021 |
31 |
An Observational Study of Mucocutaneous Manifestations among SARS-CoV-2 Patients from Three COVID-19 Dedicated Tertiary Care Centers.
62
|
Mohta A...Bha Rgava G
|
34667754 |
2021 |
32 |
Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.
62
|
Kofler K...Kofler L
|
33779349 |
2021 |
33 |
Rivaroxaban for treatment of livedoid vasculopathy: A systematic review.
62
|
Gao Y...Jin H
|
34197012 |
2021 |
34 |
A novel use of intermittent low dose dabigatran for maintenance of remission in livedoid vasculopathy.
62
|
Rajan M B...Agrawal A
|
34028946 |
2021 |
35 |
Cutaneous involvement by T-cell prolymphocytic leukemia presenting as livedoid vasculopathy.
62
|
Leckey BD...Al-Rohil RN
|
33837964 |
2021 |
36 |
Livedoid vasculopathy: A challenging disease to diagnose.
62
|
Kurt T...Acar B
|
32619286 |
2021 |
37 |
Recrudescence of livedoid vasculopathy induced by COVID-19.
62
|
Valentim FO...Miot HA
|
33527356 |
2021 |
38 |
Direct immunofluorescence findings in livedoid vasculopathy: a 10-year study and literature review.
62
|
Nuttawong S...Rujitharanawong C
|
32986882 |
2021 |
39 |
Methylene tetrahydrofolate reductase C677T polymorphism in Korean livedoid vasculopathy patients.
62
|
Lee JS...Cho S
|
32599117 |
2021 |
40 |
Livedoid vasculopathy in 75 Brazilian patients in a single-center institution: Clinical, histopathological and therapy evaluation.
62
|
Criado PR...Sotto MN
|
33496999 |
2021 |
41 |
Remission of long-standing livedoid vasculopathy using a whole foods plant-based diet with symptoms recurrent on re-challenge with standard Western diet.
62
|
Smith M...Duncan B
|
33622761 |
2021 |
42 |
Livedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature.
62
|
Rujitharanawong C...Nuttawong S
|
33219608 |
2021 |
43 |
From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy.
62
|
Criado PR...Fabro AT
|
33219572 |
2021 |
44 |
Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy.
62
|
Gao Y...Jin H
|
33043622 |
2020 |
45 |
Livedoid Vasculopathy Associated with Antiphospholipid Antibody Presenting with Leg Ulcer.
62
|
Kapur SV...Oswal JS
|
32451825 |
2020 |
46 |
A Case of Livedoid Vasculopathy Successfully Treated with Sulodexide.
62
|
Song CH...Seo HM
|
33911794 |
2020 |
47 |
Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.
62
|
Jia E...Zhang J
|
33112475 |
2020 |
48 |
[Diagnosis and treatment of vasculitic ulcerations].
62
|
Mitschang C...Gorge T
|
32997218 |
2020 |
49 |
Unraveling the mystery of Covid-19 cytokine storm: From skin to organ systems.
62
|
Garg S...Agarwal R
|
32559324 |
2020 |
50 |
[Non-healing wounds].
62
|
van Erp FC...van Montfrans C
|
33201630 |
2020 |